( AMEX:PFNX )

News from Pfenex Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 08, 2017, 08:00 ET Pfenex to Present at the 2017 JMP Healthcare Conference

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


May 08, 2017, 16:05 ET Pfenex Reports First Quarter 2017 Results and Provides Business Update

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Apr 03, 2017, 10:00 ET Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Mar 31, 2017, 16:05 ET William R. Rohn Announces Plans To Retire As Chairman And Board Member

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Mar 15, 2017, 16:05 ET Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Mar 01, 2017, 08:00 ET Pfenex To Report Fourth Quarter and Full Year 2016 Results and Provide Business Update on Wednesday, March 15, 2017

Pfenex Inc. (NYSE MKT: PFNX) announced today that its fourth quarter and full year 2016 financial results will be released on Wednesday, March 15,...


Feb 10, 2017, 06:00 ET Pfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high-value...


Jan 24, 2017, 08:00 ET Pfenex Announces Leadership Transition

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Dec 01, 2016, 17:00 ET Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules

Pfenex Inc. (NYSE MKT: PFNX) ("Pfenex" or the "Company"), a clinical-stage biotechnology company engaged in the development of biosimilar...


Nov 09, 2016, 16:05 ET Pfenex Reports Third Quarter 2016 Results and Provides Business Update

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value...


Oct 26, 2016, 18:30 ET Pfenex To Report Third Quarter 2016 Results and Provide Business Update on Wednesday, November 9, 2016

Pfenex Inc. (NYSE MKT: PFNX) announced today that its third quarter 2016 financial results will be released on Wednesday, November 9, 2016, after...


Oct 19, 2016, 18:00 ET Pfenex Inc. Announces Formation of Scientific Advisory Board

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, difficult to manufacture...


Oct 03, 2016, 18:00 ET Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules

 Pfenex Inc. (NYSE MKT: PFNX) ("Pfenex" or the "Company"), a clinical-stage biotechnology company engaged in the development of biosimilar...


Aug 08, 2016, 07:30 ET Pfenex Reports Second Quarter 2016 Results and Provides Business Update

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high...


Aug 08, 2016, 07:30 ET Pfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results

 Pfenex Inc. (NYSE MKT: PFNX) announced today that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis®,...


Aug 08, 2016, 07:30 ET Pfenex Announces Positive Anthrax Vaccine Study Results

 Pfenex Inc. (NYSE MKT: PFNX) announced today positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax vaccine...


Jul 28, 2016, 16:05 ET Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies

 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz...


Jul 27, 2016, 08:30 ET Pfenex To Report Second Quarter 2016 Results and Provide Business Update on Monday, August 8, 2016

Pfenex Inc. (NYSE MKT: PFNX) announced today that its second quarter 2016 financial results will be released on Monday, August 8, 2016, before...


May 09, 2016, 16:05 ET Pfenex Reports Positive Top-Line Bioequivalence Data for PF708

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high...


May 09, 2016, 16:05 ET Pfenex Reports First Quarter 2016 Results and Provides Business Update

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high...


Apr 25, 2016, 08:00 ET Pfenex to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced...


Mar 10, 2016, 16:05 ET Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high...


Mar 07, 2016, 08:30 ET Pfenex to Present at the 2016 Barclays Global Healthcare Conference

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that...


Feb 25, 2016, 08:00 ET Pfenex To Report Fourth Quarter and Full Year 2015 Results and Provide Business Update on Thursday, March 10, 2016

 Pfenex Inc. (NYSE MKT: PFNX) announced today that its fourth quarter and full year 2015 financial results will be released on Thursday, March...


Dec 16, 2015, 06:45 ET Selling Shareholder Prices Secondary Offering

 Pfenex Inc. (NYSE MKT: PFNX) announced today the pricing of its secondary offering of 600,000 shares of its common stock at a price to the...